EMVision Medical Devices (ASX:EMV) reported positive results from a study assessing the effectiveness of its neurodiagnostic technology algorithm in early detection of strokes, according to a Tuesday filing with the Australian bourse.

The study enrolled 307 participants, including 277 acute suspected stroke patients, who were scanned using the company's brain scanner device, the filing said.

The study's objective was to collect matched scans from its brain scanner device and CT/MRI ground-truth brain scans to advance the scanner's AI-based diagnostic algorithms.

The data collected steadily improved the performance of the diagnostic algorithms, and the results of the study will be submitted for publication following peer review, the filing added.

Following the results, EMVison can now proceed to the validation trial. The company expects trial costs of about AU$ 4 million, to be funded from cash reserves.